Nuvectis Pharma, Inc. — Director's Dealing 2022

May 19, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nuvectis Pharma, Inc. (NVCT)
CIK: 0001875558
Period of Report: 2022-05-17

Reporting Person: BENTSUR RON (Director, Chairman & CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-05-17	Common Stock	P	200	$19.77	Acquired	2959604	Direct
2022-05-17	Common Stock	P	110	$20.83	Acquired	2959714	Direct
2022-05-18	Common Stock	P	700	$20.60	Acquired	2960414	Direct
2022-05-18	Common Stock	P	1000	$18.49	Acquired	2961414	Direct

Footnotes

F1: Reflects the weighted average purchase price. The range of prices for the shares purchased was $19.75 to $19.79. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

F2: Includes 96,759 shares of restricted stock and 120,000 restricted stock units.

F3: Reflects the weighted average purchase price. The range of prices for the shares purchased was $20.10 to $20.82. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.

F4: Reflects the weighted average purchase price. The range of prices for the shares purchased was $18.45 to $18.50. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price.